Philips, N-of-One Team Up On Cancer Genomics
News Dec 06, 2016
Royal Philips and N-of-One, Inc. announced they are teaming up to enhance the capabilities of Philips’ IntelliSpace Genomics solution. The two companies will collaborate on the clinical analysis, annotation and interpretation of oncology cases processed through Philips new precision medicine solution for oncology. This healthcare informatics solution integrates genomic information with full patient context to empower clinicians with precision diagnostics and therapeutics, to enable them to measure the success of precision healthcare programs.
Profiling tumors using genomic information is critical for complex cancer cases, yet challenges remain in rapidly and accurately interpreting genomic findings in the context of a patient’s condition. While most cancer patients have thousands of gene variants and mutations, only a small number drive the individual’s specific cancer or may have actionable therapeutic implications for a particular patient.
The Philips IntelliSpace Genomics solution, which uniquely integrates complete patient information, is coupled with N-of-One’s rich experience and extensive knowledge-bases. For the first time, clinicians will have full access to N-of-One’s variant database during the case filtering and interpretation process, providing them ready access to the vast amount of available reference literature, guidelines, and evidence, in a fully interactive framework. The aim is to help clinicians determine which treatment options, clinical trials or medications, are best suited to a specific case.
Story from N-of-One. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Blood Test for Colitis Screening Could Reduce Dependence on ColonoscopyNews
A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test.READ MORE
Agilent Obtains U.S. FDA Approval for GenetiSure Dx Postnatal AssayNews
Agilent Technologies has obtained 510(k) clearance from the FDA for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization (CGH) assay for diagnostic use.READ MORE
Endomag Receives CE Mark Approval for Magseed Breast Cancer Localisation TechnologyNews
Endomag can now use Magseed, an accurate marker for surgeons to use during breast cancer removal surgery.READ MORE
Comments | 0 ADD COMMENT
13th Edition of International Conference on Pediatric Gastroenterology
Aug 02 - Aug 04, 2018